Spotlight on New Oncology Drugs: Access, Costs, and Use

David L. DeRemer, PharmD, BCOP, and Bently P. Doonan, MD, MS, share a perspective on ocular toxicities associated with MEK inhibition.

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

The 10-year cumulative local recurrence rate in patients with early breast cancer receiving accelerated partial breast irradiation with multi-catheter brachytherapy does not significantly differ from those receiving whole-breast irradiation following breast-conserving surgery.

Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.

Experts review the most recent data and discuss current strategies for the management of HR+ metastatic breast cancer.

According to a retrospective analysis, bendamustine treatment correlates with a higher risk of infection and second malignancy compared with other treatments for indolent B-cell lymphoma.